Eli Lilly's Gene-Editing Cholesterol Therapy Shows Strong Early Results, Gets FDA Fast-Track
LLY sits 71% above its 52-week low of $623.78.
Summary
Eli Lilly announced positive Phase 1b clinical trial results for Verve-102, its experimental gene-editing therapy for high cholesterol. The treatment achieved up to an 88% reduction in PCSK9 protein levels and up to a 62% reduction in LDL cholesterol, with effects sustained for 18 months and no serious adverse events. The FDA has granted fast-track designation, accelerating its development. This adds a highly promising, innovative gene-editing asset to Eli Lilly's pipeline, building on recent successes with new drug approvals and strong financial performance. A Phase 2 study is expected to begin by year-end.
At the time of this announcement, LLY was trading at $1,064.59 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.